KR20260061467A - 고체 형태의 tert-부틸 (S)-2-((2S,3R)-1-아미노-3-히드록시-1-옥소부탄-2-일)-1-옥소-2,5-디아자스피로[3.4]옥탄-5-카르복실레이트 및 제조 방법 - Google Patents

고체 형태의 tert-부틸 (S)-2-((2S,3R)-1-아미노-3-히드록시-1-옥소부탄-2-일)-1-옥소-2,5-디아자스피로[3.4]옥탄-5-카르복실레이트 및 제조 방법

Info

Publication number
KR20260061467A
KR20260061467A KR1020267012575A KR20267012575A KR20260061467A KR 20260061467 A KR20260061467 A KR 20260061467A KR 1020267012575 A KR1020267012575 A KR 1020267012575A KR 20267012575 A KR20267012575 A KR 20267012575A KR 20260061467 A KR20260061467 A KR 20260061467A
Authority
KR
South Korea
Prior art keywords
compound
crystalline form
solid
powder
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267012575A
Other languages
English (en)
Korean (ko)
Inventor
시아오다 유안
샤오신 펭
대니 티. 딘
윌리암. 알. 페로
Original Assignee
노렉스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노렉스, 인크. filed Critical 노렉스, 인크.
Publication of KR20260061467A publication Critical patent/KR20260061467A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
KR1020267012575A 2019-06-24 2020-06-23 고체 형태의 tert-부틸 (S)-2-((2S,3R)-1-아미노-3-히드록시-1-옥소부탄-2-일)-1-옥소-2,5-디아자스피로[3.4]옥탄-5-카르복실레이트 및 제조 방법 Pending KR20260061467A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962865826P 2019-06-24 2019-06-24
US62/865,826 2019-06-24
KR1020227002351A KR102958083B1 (ko) 2019-06-24 2020-06-23 고체 형태의 tert-부틸 (S)-2-((2S,3R)-1-아미노-3-히드록시-1-옥소부탄-2-일)-1-옥소-2,5-디아자스피로[3.4]옥탄-5-카르복실레이트 및 제조 방법
PCT/US2020/039163 WO2020263847A1 (en) 2019-06-24 2020-06-23 Solid forms of tert-butyl (s)-2-((2s,3r) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002351A Division KR102958083B1 (ko) 2019-06-24 2020-06-23 고체 형태의 tert-부틸 (S)-2-((2S,3R)-1-아미노-3-히드록시-1-옥소부탄-2-일)-1-옥소-2,5-디아자스피로[3.4]옥탄-5-카르복실레이트 및 제조 방법

Publications (1)

Publication Number Publication Date
KR20260061467A true KR20260061467A (ko) 2026-05-06

Family

ID=74060350

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020267012575A Pending KR20260061467A (ko) 2019-06-24 2020-06-23 고체 형태의 tert-부틸 (S)-2-((2S,3R)-1-아미노-3-히드록시-1-옥소부탄-2-일)-1-옥소-2,5-디아자스피로[3.4]옥탄-5-카르복실레이트 및 제조 방법
KR1020227002351A Active KR102958083B1 (ko) 2019-06-24 2020-06-23 고체 형태의 tert-부틸 (S)-2-((2S,3R)-1-아미노-3-히드록시-1-옥소부탄-2-일)-1-옥소-2,5-디아자스피로[3.4]옥탄-5-카르복실레이트 및 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227002351A Active KR102958083B1 (ko) 2019-06-24 2020-06-23 고체 형태의 tert-부틸 (S)-2-((2S,3R)-1-아미노-3-히드록시-1-옥소부탄-2-일)-1-옥소-2,5-디아자스피로[3.4]옥탄-5-카르복실레이트 및 제조 방법

Country Status (12)

Country Link
US (1) US20220267341A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986399A4 (cg-RX-API-DMAC7.html)
JP (2) JP7617043B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260061467A (cg-RX-API-DMAC7.html)
CN (1) CN114364380A (cg-RX-API-DMAC7.html)
AU (1) AU2020304001B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021026380A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144600A1 (cg-RX-API-DMAC7.html)
IL (1) IL289198A (cg-RX-API-DMAC7.html)
MA (1) MA56550A (cg-RX-API-DMAC7.html)
MX (2) MX2022000069A (cg-RX-API-DMAC7.html)
WO (1) WO2020263847A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI887245B (zh) * 2019-06-24 2025-06-21 美商諾雷克斯股份有限公司 用於產生二氮雜螺內醯胺化合物之方法及中間物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
ES2416354T3 (es) * 2005-06-21 2013-07-31 Ajinomoto Co., Inc. Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo
MX2011003015A (es) * 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
JP6419087B2 (ja) * 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド スピロラクタム系nmda受容体モジュレーターおよびその使用
CA2898861C (en) * 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
TWI738748B (zh) * 2016-03-28 2021-09-11 日商武田藥品工業有限公司 2-[(2s)-1-氮雜雙環[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物之晶形
PE20190174A1 (es) * 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
TWI887245B (zh) * 2019-06-24 2025-06-21 美商諾雷克斯股份有限公司 用於產生二氮雜螺內醯胺化合物之方法及中間物

Also Published As

Publication number Publication date
CN114364380A (zh) 2022-04-15
JP2022539342A (ja) 2022-09-08
WO2020263847A1 (en) 2020-12-30
MX2025002579A (es) 2025-04-02
US20220267341A1 (en) 2022-08-25
MA56550A (fr) 2022-04-27
EP3986399A4 (en) 2023-06-07
AU2020304001A1 (en) 2022-01-27
EP3986399A1 (en) 2022-04-27
JP7617043B2 (ja) 2025-01-17
CA3144600A1 (en) 2020-12-30
AU2020304001B2 (en) 2026-04-09
IL289198A (en) 2022-02-01
MX2022000069A (es) 2022-05-24
KR20220061088A (ko) 2022-05-12
JP7858096B2 (ja) 2026-05-13
BR112021026380A2 (pt) 2022-05-10
JP2025069143A (ja) 2025-04-30
KR102958083B1 (ko) 2026-04-27

Similar Documents

Publication Publication Date Title
EP2970123B1 (en) Salt of omecamtiv mecarbil and process for preparing salt
JP7644027B2 (ja) Btk阻害剤の結晶形態
CA2908879C (en) Crystal of pyrrole derivative and method for producing the same
JP5635181B2 (ja) ニトロイミダゾール系化合物、その製造方法および用途
KR20150001802A (ko) 피닥소마이신의 고상 형태 및 이의 제조 방법
JP7858096B2 (ja) tert-ブチル(S)-2-((2S,3R)-1-アミノ-3-ヒドロキシ-1-オキソブタン-2-イル)-1-オキソ-2,5-ジアザスピロ[3.4]オクタン-5-カルボキシレートの固体形態およびそれらを調製する方法
US11584715B2 (en) Crystalline form of sofpironium bromide and preparation method thereof
AU2021215426B2 (en) Polymorph of EP4 receptor antagonist, preparation method therefor and use thereof
CN121605107A (zh) 2-[(3r)-2-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4[4-(氧杂环丁烷-3-基)哌嗪-1-基]-戊-2-烯腈及其溶剂化物形式的制备方法
CA3091528A1 (en) Crystal form of oxopicolinamide derivative and preparation method therefor
EA044016B1 (ru) Твердые формы трет-бутил(s)-2-((2s,3r)-1-амино-3-гидрокси-1-оксобутан-2-ил)-1-оксо-2,5-диазаспиро[3.4]октан-5-карбоксилата и способы их получения
WO2011029005A1 (en) Crystalline forms of fesoterodine fumarate and fesoterodine base
HK40068368B (en) Crystalline form of sofpironium bromide and preparation method thereof
CN103781777A (zh) 6-(哌啶-4-基氧基)-2h-异喹啉-1-酮盐酸盐的多晶型物
CN118475589A (zh) 一种神经激肽-1拮抗剂前药化合物的晶型
HK40035144B (en) Preparation process of two compounds
CA2232059A1 (en) Phenol derivatives with pharmaceutical activity
HK1218544B (en) Salt of omecamtiv mecarbil and process for preparing salt

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)